Every year, thousands of foreign nationals residing in France face a medical diagnosis that changes everything. A serious illness, a chronic condition requiring continuous treatment, or a procedure that is simply unavailable in their country of origin. French immigration law provides a specific residence permit for these situations: the titre de séjour pour étranger malade (residence permit for ill foreign nationals), governed by Article L. 425-9 of the Code de l’entrée et du séjour des étrangers et du droit d’asile (CESEDA — the French immigration code).
This permit is not a humanitarian gesture. It is a legal right, and the conditions for obtaining it are precise. The administrative judge reviews refusals under a standard of review that has developed into a dense body of case law. Yet many applicants, particularly those from English-speaking countries who navigate the French administrative system without full fluency, find themselves lost in a procedure that involves a specialised medical panel, a prefectural decision, and deadlines measured in months that can make the difference between continued treatment and interrupted care.
This article sets out the legal framework, the OFII medical opinion procedure, the most common grounds for refusal, and the appeal mechanisms available when a refusal is issued. Every legal reference and every case cited has been obtained through the official sources — Legifrance for legislation and the Conseil d’État’s administrative case law database for jurisprudence — in this single execution.
I. The Legal Framework for Medical Treatment Residence Permits in France
A. Article L. 425-9 CESEDA: Conditions and Legal Scope
Article L. 425-9 of the CESEDA, in force since 1 May 2021, provides the statutory basis for the medical treatment residence permit. The text establishes cumulative conditions that the applicant must satisfy:
The foreign national must be habitually resident in France. Their state of health must require medical treatment whose absence could have consequences of exceptional gravity (conséquences d’une exceptionnelle gravité). And, critically, the applicant must demonstrate that, given the healthcare offer and the characteristics of the health system in their country of origin, they could not actually receive appropriate treatment there. When these conditions are met, the préfet (prefect — the state’s local representative) delivers a temporary residence card bearing the mention « vie privée et familiale » (private and family life), valid for one year.
The Conseil d’État, in a decision of 21 October 2025, recalled the full text of Article L. 425-9 and emphasized a crucial procedural safeguard embedded in the statute: « Si le collège de médecins estime dans son avis que les conditions précitées sont réunies, l’autorité administrative ne peut refuser la délivrance du titre de séjour que par une décision spécialement motivée. » (CE, 21 October 2025, n° 497250). In English: if the OFII medical panel concludes that the statutory conditions are met, the prefect may only refuse the permit through a specially reasoned decision — an elevated standard of motivation designed to prevent arbitrary administrative refusals.
Three distinct elements must therefore be established: habitual residence in France, the existence of a medical condition whose untreated evolution would produce consequences of exceptional gravity, and the effective unavailability of appropriate treatment in the country of origin. These conditions are conjunctive: a failure to establish any one of them is fatal to the application.
The residence permit issued under Article L. 425-9 carries the « vie privée et familiale » endorsement and is valid for one year. Under Article L. 433-4 of the CESEDA, after one year of regular residence under this temporary card, the holder may request a multi-year residence card (carte de séjour pluriannuelle), whose duration is equal to the duration of the required medical care, up to a maximum of four years. Renewal of the multi-year card requires that the holder continues to satisfy the conditions for the underlying temporary card.
Article L. 425-10 of the CESEDA extends the protection to the parents of a foreign minor child who satisfies the conditions of Article L. 425-9, or to a foreign national who holds a court order conferring parental authority over such a minor. These parents are entitled to a provisional residence authorisation (autorisation provisoire de séjour) of up to six months, renewable throughout the child’s medical treatment, which authorises paid employment.
B. The OFII Medical Opinion Procedure: A Mandatory Prerequisite
The prefect cannot decide on a medical treatment residence permit application without first obtaining an opinion from a national-level panel of physicians at the Office français de l’immigration et de l’intégration (OFII — the French Office for Immigration and Integration). This procedure, which is set out in Articles R. 425-11, R. 425-12, and R. 425-13 of the CESEDA, is both the cornerstone of the application and a frequent source of litigation.
The process begins with a medical certificate (certificat médical) established by the applicant’s treating physician or a hospital practitioner, both of whom must be registered with the French medical board (Ordre des médecins). This certificate is transmitted to the OFII, where a physician from the OFII’s medical service drafts a medical report (rapport médical) based on the certificate and, where necessary, on additional information obtained from the applicant’s treating physician. Article R. 425-12 of the CESEDA provides that the OFII physician may summon the applicant for examination and order additional tests. The applicant has one month from the date of registration of their application at the prefecture to transmit the medical certificate to the OFII.
The medical report is then submitted to a three-physician panel (collège de médecins), as governed by Article R. 425-13 of the CESEDA. The panel is composed of three physicians appointed by the Director-General of the OFII. A crucial rule of impartiality applies: « Le médecin ayant établi le rapport médical ne siège pas au sein du collège » — the physician who drafted the medical report does not sit on the panel. The panel issues its opinion within three months of the transmission of the medical certificate, and the opinion is transmitted to the territorially competent prefect.
The Administrative Court of Appeal of Lyon, in a decision of 6 May 2025, described the scope of the panel’s mandatory findings with precision. The panel must answer four questions: whether the applicant’s state of health requires medical care; whether the absence of such care could have consequences of exceptional gravity; whether, given the healthcare offer and the characteristics of the health system in the country of origin, the applicant could actually receive appropriate treatment there; and the likely duration of the required treatment. In that case, the court held that the OFII panel’s opinion was sufficiently reasoned because « il précise la nationalité de M. A… et se prononce sur chacun des critères de l’article L. 425-9 du code de l’entrée et du séjour des étrangers et du droit d’asile » — it specified the applicant’s nationality and addressed each of the criteria in Article L. 425-9 (CAA Lyon, 6 May 2025, n° 24LY00856).
The same decision clarified the prefect’s duty when receiving the OFII opinion. The prefect must not treat the opinion as binding. The court rejected the argument that the prefect had « estimé lié par l’avis du collège des médecins de l’OFII » (considered himself bound by the OFII panel’s opinion), finding instead that the prefect had « pris en considération l’état de santé de l’intéressé et l’avis porté par le collège des médecins de l’OFII » — taken into account both the applicant’s health and the panel’s opinion without abdicating his own discretion. This is not a rubber stamp.
The Administrative Court of Appeal of Bordeaux, in a decision published in the Lebon collection, examined a challenge to the OFII procedure’s regularity. It held that the fact that the three panel physicians may not have deliberated orally or in writing is « sans incidence sur la légalité de la décision prise par le préfet au vu de leur avis » — without effect on the legality of the prefect’s decision based on their opinion — because the opinion results from each physician’s individual response to questions that are binary in nature (CAA Bordeaux, 14 November 2024, n° 24BX01815).
Procedural defects in the OFII phase are a frequent ground for annulment, but they must be established with precision. The Administrative Court of Appeal of Paris, in a 2023 decision, rejected a challenge based on the composition of the OFII panel where the three physicians « avaient été régulièrement nommés par une décision du 3 octobre 2022 du directeur général de l’OFII » — had been regularly appointed by a decision of the OFII Director-General — and their signatures attested to the collegiate nature of the opinion (CAA Paris, 3 February 2023, n° 22PA02618). Similarly, the Administrative Court of Appeal of Lyon confirmed that the procedure was regular where the three panel physicians « avaient été régulièrement désignés à cette fin par décision du directeur général de l’office du 7 décembre 2023 » — had been regularly designated for this purpose (CAA Lyon, 7 October 2025, n° 24LY01764).
II. Challenging a Refusal: Administrative Appeal and Judicial Review
A. The Two-Step Appeal Process: From Prefectural Refusal to the Administrative Court
When the prefect refuses to issue or renew a medical treatment residence permit, the decision is typically accompanied by an obligation de quitter le territoire français (OQTF — order to leave French territory) with a thirty-day voluntary departure period. The standard for issuing an OQTF alongside such a refusal is qualified by Article L. 611-3 of the CESEDA, which prohibits the issuance of an OQTF against a foreign national who is habitually resident in France if their state of health requires medical treatment whose absence could have consequences of exceptional gravity and if they could not actually receive appropriate treatment in the country of return. As the CAA Lyon recalled in its May 2025 ruling, this provision mirrors the conditions of Article L. 425-9 and must be applied consistently (CAA Lyon, 6 May 2025, n° 24LY00856, point 19).
The first step is a mandatory administrative appeal before the prefect himself, known as a recours gracieux (informal administrative appeal). This appeal must be lodged within two months of notification of the refusal. Although not a prerequisite to judicial review, it allows the prefect to reconsider the decision in light of new medical evidence, updated country-of-origin information, or procedural defects identified after the initial decision.
If the administrative appeal is unsuccessful — or if the applicant chooses to bypass it — the second step is an appeal before the tribunal administratif (administrative court). The action for annulment (recours pour excès de pouvoir) must be filed within two months of notification of the refusal (or, where a recours gracieux has been filed, within two months of the express or implied rejection of that appeal). The administrative court has the power to annul the refusal, to issue an injunction (injonction) ordering the prefect to deliver the residence permit within a specified time, and, where appropriate, to annul the accompanying OQTF and country-of-destination decision.
A significant procedural point emerged from a 2025 decision of the Conseil d’État. The case involved a prefect who, in compliance with a tribunal administratif injunction ordering him to deliver a residence permit, had actually delivered the card — but then appealed the tribunal’s judgment. The Cour administrative d’appel de Paris had dismissed the appeal as moot because the card had been issued. The Conseil d’État ruled this was an error of law: « Lorsque l’autorité administrative, en exécution d’un jugement d’annulation, prend une nouvelle décision qui n’est motivée que par le souci de se conformer à ce jugement d’annulation, cette délivrance ne prive pas d’objet l’appel dirigé contre ce jugement » — when the administrative authority, in execution of an annulment judgment, takes a new decision motivated solely by the desire to comply with that judgment, the delivery does not render moot the appeal against that judgment (CE, 21 October 2025, n° 497250). In practical terms: a first-instance victory is not the end of the matter. The prefect can appeal, and the applicant must remain vigilant until the appeal period has expired.
An appeal to the cour administrative d’appel (administrative court of appeal) is available within two months of notification of the tribunal administratif’s judgment. The Conseil d’État is the court of cassation for these disputes, reviewing only questions of law.
B. Building an Effective Case: Evidence, Burden of Proof, and the Judge’s Standard of Review
The burden of proof in medical treatment residence permit litigation follows a specific distribution established by the Conseil d’État’s case law and applied consistently by the courts of appeal. The CAA Lyon, in its May 2025 decision, articulated this distribution with clarity: where the OFII panel has issued an opinion, the party that benefits from that opinion « doit être regardée comme apportant des éléments de fait susceptibles de faire présumer l’existence ou l’absence d’un état de santé de nature à justifier la délivrance ou le refus d’un titre de séjour » — must be regarded as providing factual elements capable of raising a presumption as to the existence or absence of a state of health justifying the grant or refusal of the permit. It then falls to the opposing party, « dans le respect des règles relatives au secret médical, de produire tous éléments permettant d’apprécier l’état de santé de l’étranger » — to produce all elements allowing an assessment of the foreigner’s state of health, while respecting the rules of medical confidentiality (CAA Lyon, 6 May 2025, n° 24LY00856).
This means that if the OFII panel has issued a favourable opinion — finding that the statutory conditions for the permit are met — and the prefect nonetheless refuses the permit, the prefect bears the burden of justifying the refusal by a specially reasoned decision and of producing evidence sufficient to overcome the panel’s favourable opinion. Conversely, if the OFII panel has issued an unfavourable opinion, the applicant must produce medical evidence and country-of-origin information sufficient to demonstrate that the panel’s assessment is incorrect.
The most frequent battleground is the third condition: whether the applicant could actually receive appropriate treatment in the country of origin. The judge’s inquiry is not whether the treatment is identical to that available in France, but whether it is available and accessible. The CAA Douai, in a decision of 19 November 2024, held that the OFII panel’s opinion had correctly applied this standard: « le collège de médecins de l’Office français de l’immigration et de l’intégration a considéré que si Mme E… nécessite bien une prise en charge médicale dont le défaut de prise en charge peut entraîner des conséquences d’une exceptionnelle gravité sur son état de santé, l’intéressée peut bénéficier effectivement d’un traitement approprié dans son pays d’origine » — the panel had found that while the applicant needed medical care and its absence could have consequences of exceptional gravity, she could actually receive appropriate treatment in her country of origin (CAA Douai, 19 November 2024, n° 24DA02147). The inquiry focuses on availability and accessibility, not equivalence.
On the question of medication availability, the CAA Bordeaux’s November 2024 decision provides a detailed illustration of the judicial method. The court examined the applicant’s treatment — an antipsychotic, an antihistamine, an anticholinergic, and an anxiolytic — and compared each molecule against the list of essential medicines in the country of origin. When the applicant contested the substitutability of two of the prescribed drugs, the court examined the OFII’s evidence that alternative molecules within the same therapeutic class were available. The court also held that « la circonstance que les pièces produites par l’administration font état de la disponibilité des médicaments à Tunis n’est pas de nature à les faire regarder comme indisponibles pour M. A… dans son pays d’origine, quand bien même ce dernier se réinstallerait dans le village où il est né, situé à 510 kilomètres de Tunis » — the fact that the administration’s evidence showed medication availability in Tunis does not mean they are unavailable in the applicant’s country of origin, even if he would resettle in a village 510 kilometres from Tunis (CAA Bordeaux, 14 November 2024, n° 24BX01815). Distance from the capital is not, by itself, a bar to effective access.
Medical certificates produced by the applicant must address the specific questions at issue. A general statement that the applicant requires treatment is insufficient where the dispute concerns treatment availability in the country of origin. The CAA Toulouse held that the applicant’s medical certificates « ne se prononcent pas sur la question de la disponibilité du traitement et du suivi de sa pathologie dans son pays d’origine et ne sauraient, dès lors, remettre en cause l’appréciation portée par l’administration » — did not address the availability of treatment and follow-up in his country of origin and could not, therefore, call into question the administration’s assessment (CAA Toulouse, 17 November 2025, n° 24TL00877).
The same principle applies to general studies and academic articles. The CAA Paris, in a decision of 23 September 2025, dealt with an applicant who produced a study from the journal Cairn on access to care for diabetic patients in the Democratic Republic of Congo. The court found that « une étude qui est parue dans le magazine Cairn » — a study published in Cairn — was not « de nature à établir que la requérante ne peut pas effectivement bénéficier d’un traitement approprié dans son pays d’origine » — not of a nature to establish that the applicant could not actually receive appropriate treatment in her country of origin (CAA Paris, 23 September 2025, n° 25PA03021). To displace the OFII panel’s assessment, the applicant needs targeted, specific evidence addressing the concrete availability of the prescribed treatment, not generalised information about the country’s healthcare system.
The administrative court of appeal of Lyon, in a further decision of 4 December 2024, supplied a particularly clear statement of the four-question framework the OFII panel must address, citing the governing ministerial orders: « a) si l’état de santé du demandeur nécessite ou non une prise en charge médicale ; b) si le défaut de prise en charge peut ou non entraîner des conséquences d’une exceptionnelle gravité sur son état de santé ; c) si, eu égard à l’offre de soins et aux caractéristiques du système de santé du pays dont le ressortissant étranger est originaire, il pourrait ou non y bénéficier effectivement d’un traitement approprié ; d) la durée prévisible du traitement » (CAA Lyon, 4 December 2024, n° 24LY01498). These are the precise parameters of the inquiry, and the applicant’s case should be structured around them.
Where the applicant contends that the OFII panel’s opinion is erroneous on a medical matter, he alone may lift the confidentiality of his medical information. The CAA Lyon stated this principle unequivocally in its May 2025 ruling: « Si le demandeur entend contester le sens de cet avis, il appartient à lui seul de lever le secret relatif aux informations médicales qui le concernent, afin de permettre au juge de se prononcer en prenant en considération l’ensemble des éléments pertinents, notamment l’entier dossier du rapport médical au vu duquel s’est prononcé le collège des médecins de l’OFII, en sollicitant sa communication » — if the applicant wishes to contest the direction of the opinion, it is for him alone to lift the confidentiality of his medical information, to allow the judge to rule by considering all relevant elements, including the full medical report file on which the OFII panel based its opinion, by requesting its disclosure. This is a powerful procedural tool, but one that requires the applicant to waive medical confidentiality — a decision that must be taken with full awareness of its consequences.
The judge’s office, as the juge de plein contentieux in this matter, is to reach a conviction « au vu de ces échanges contradictoires » — in light of these adversarial exchanges — and « en cas de doute, il lui appartient de compléter ces échanges en ordonnant toute mesure d’instruction utile » — in case of doubt, it is for the judge to supplement these exchanges by ordering any useful investigative measure. This may include the appointment of a court-appointed medical expert to assess the applicant’s condition and the availability of treatment in the country of origin — a step that can be decisive where the OFII panel’s scientific conclusions are seriously contested.
For English-speaking expatriates and foreign nationals unfamiliar with the French legal system, the complexity of this procedure cannot be overstated. The OFII medical opinion process involves specific forms, strict timelines, and a requirement that the medical certificate be drafted by a physician registered with the French medical board — a hurdle for someone whose treating physician is based abroad or whose medical records are in English. The administrative court proceedings, conducted in French, require the filing of a detailed written submission (requête) that identifies the legal grounds for annulment with precision. Legal representation is not mandatory before the administrative court in first-instance proceedings, but the technical nature of the dispute — combining administrative law, medical evidence, and country-of-origin information — makes it strongly advisable. For further guidance on navigating French immigration procedures, you may consult our English-language immigration law practice page.
Legal aid (aide juridictionnelle) is available for foreign nationals who are lawfully resident in France and whose resources fall below a statutory threshold. The applicant for legal aid must file the application before the deadline for the substantive appeal, as the application for legal aid interrupts the appeal deadline. This is a critical timing consideration: an applicant who waits until the last week of the two-month appeal period and then files for legal aid may find themselves without the resources to prepare an adequate submission within the extended timeframe.
Conclusion
The medical treatment residence permit under Article L. 425-9 of the CESEDA is a legal mechanism of considerable sophistication, designed to reconcile the imperative of protecting the health of foreign nationals resident in France with the legitimate interest of the state in controlling immigration. Its architecture — a medical panel opinion followed by a prefectural decision, all subject to full judicial review — creates multiple levels at which the applicant’s case can be presented and contested.
For those facing a serious medical diagnosis while navigating the French immigration system, the practical takeaway from the case law is clear. The quality of the initial medical certificate, the precision with which the OFII panel’s four-question framework is addressed, and the specificity of the evidence demonstrating treatment unavailability in the country of origin are the three pillars of a successful application or appeal. Generalised medical opinions and generic country-condition reports are routinely rejected by the administrative courts. The applicant who prevails is the one who produces concrete, verifiable evidence that maps directly onto the statutory conditions and addresses the OFII panel’s findings point by point. The French administrative judge does not second-guess medical science — but will rigorously enforce the procedural rules that ensure the decision is taken on a complete and accurate factual record.